185 BETA-BLOCKERS OR CALCIUM CHANNEL BLOCKERS IN HYPERTROPHIC CARDIOMYOPATHY

Abstract Background Guidelines recommend betablockers (BB) as first line therapy in symptomatic patients with hypertrophic cardiomyopathy (HCM). A secondary role the therapeutic algorithm is assigned to non-dihydropyridine calcium channel blockers (ND-CCB). Since no randomized comparison trials between two drugs have been made so far, aim of present analysis was evaluate prognostic impact BB and ND-CCB a cohort HCM, either obstructive or not. Methods From 1434 diagnosis HCM included French register REMY, we retrospectively analysed 601 individuals treated ND-CCB. Patients taking both none, who already had an implantable cardioverter defibrillator pacemaker undergone procedure atrial fibrillation (AF) ablation septal reduction were excluded. Results Out patients, 545 (91%) 56 (9%) At 8-year follow-up differences observed regard composite endpoint cardiovascular death, hospitalization for heart failure AF (133 [24%] vs. 9 [16%] respectively, HR 1.84, 95% CI 0.94–3.63). less at long-term but experienced more drug interruptions changes. Conclusions In real-world not associated higher incidence adverse events compared therapy.